SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis , and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel In Vitro SU056 (0-10 μM approximately, 48 h) inhibits cell growth in OVCAR3/4/5/8, SKOV3 and ID8 cells。 SU056 (1 μM, 5-8 days) inhibits colony formation in a dose-dependent manner in OVCAR-8 and ID8 cells。 SU056 (1-5 μM, 6 h) arrests OVCAR8, SKOV3, and ID8 cells in the sub-G1 and G1 phases. SU056 (0-1 μM, 12 h) inhibits cell migration in OVCAR8, SKOV3, and ID8 cells. SU056 (0-5 μM, 24 h) induces apoptotic cell death in OVCAR8, SKOV3, and ID8 cells. SU056 (1-5 μM, 12 h) inhibited the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells. SU056 (0.1, 0.5, and 1 μM, 48 h) enhances the cytotoxic effects of Paclitaxel (0.1, 0.5, and 1 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OVCAR3/4/5/8, SKOV3 and ID8 cells Concentration: 0-10 μM approximately Incubation Time: 48 h Result: Inhibited cell growth with IC 50 values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM. Cell Migration AssayCell Line: OVCAR8, SKOV3, and ID8 cells Concentration: 0, 0.5, 1 μM Incubation Time: 12 h Result: Dose-dependently inhibited cell migration. Western Blot AnalysisCell Line: OVCAR8 cell Concentration: 1-5 μM Incubation Time: 12 h Result: Dose-dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins. In Vivo SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells . SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice implanted (s.c.) with luciferase-expressing ID8 cells Dosage: 20 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Reduced the tumor weight by 2-fold, and is well-tolerated. Reduced the lung metastases. Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample). Form:Solid IC50& Target:YB-1
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
SU056
CAS number：2376580-08-2 molecular formula：C20H16FNO5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2376580-08-2 | molecular formula | C20H16FNO5 |
| molecular weight | 369.34 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
